An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and thymosin beta-4. The panel rejected emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem's stock remained stable after the vote. A recent study indicated peptides may help treat antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for expanded access to controversial peptides, calling for loosened oversight. The vote reflects a broader shift in how regulators view specialty peptide therapies, which have drawn growing interest from users seeking alternatives to standard drugs. Researchers say peptide treatments could reshape approaches to difficult infections, though concerns about quality persist. The committee's endorsement of four peptides opens the door for more widespread prescribing, even as watchdogs warn of short-term evidence. Sector observers note that peptide-focused companies may see heightened investor attention following the panel's decision. The rejection of emideltide, meanwhile, highlights the FDA's cautious stance on certain peptide candidates.